Sanofi India Limited — Important, 27-02-2025: Financial Result Updates

Sanofi India Limited has announced a board meeting regarding its financial results for the quarter and year ended December 31, 2024. The company reported consolidated revenue from operations of ₹5,149 crores for Q4-2024, marking an 8% increase from the previous year. Significant drivers for this growth include a double-digit increase in the diabetes portfolio and strategic partnerships in the central nervous system and cardiovascular segments.

Net profit from continuing operations for the quarter was ₹913 crores, compared to ₹697 crores in Q4-2023, reflecting a robust year-over-year increase. Earnings per share (EPS) based on continuing operations stood at ₹39.64. Profitability was supported by improved operational efficiencies, even as expenses rose due to increased marketing and operational costs.

Total operational costs rose by 7%, due to higher material and employee expenses, though cost management remains a strategic focus area. The cash flow statement indicated a net cash inflow from operating activities of ₹4,615 crores, highlighting strong operational performance.

The balance sheet remains healthy, with total assets of ₹16,118 crores and equity of ₹8,606 crores. The board has also proposed a final dividend of ₹117 per share, pending shareholder approval.

Given the consistent revenue growth, improving profit margins, and strategic focus on efficiency, investors may consider a buy position, as the company positions itself well within the pharmaceutical landscape.